5-(1-甲基-哌啶-4-基)-2-三氟甲氧基-苯基胺 | 1034618-12-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 5-(1-甲基-哌啶-4-基)-2-三氟甲氧基-苯基胺
• 英文名称: 5-(1-methyl-piperidin-4-yl)-2-trifluoromethoxy-phenylamine
• 英文别名: 5-(1-methylpiperidin-4-yl)-2-(trifluoromethoxy)aniline
• CAS: 1034618-12-6
• 化学式: C₁₃H₁₇F₃N₂O
• 分子量: 274.286
• InChiKey: UBNFSOZJNZWZME-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  38.5
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  8-iodo-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide 、 5-(1-甲基-哌啶-4-基)-2-三氟甲氧基-苯基胺 在 palladium diacetate 、 potassium carbonate 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 1-methyl-8-[5-(1-methyl-piperidin-4-yl)-2-trifluoromethoxy-phenylamino]-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
  参考文献：
  名称：

  NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor

  摘要：

  As part of our drug discovery effort, we identified and developed 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as PLK1 inhibitors. We now report the optimization of this class that led to the identification of NMS-P937, a potent, selective and orally available PLK1 inhibitor. Also, in order to understand the source of PLK1 selectivity, we determined the crystal structure of PLK1 with NMS-P937. The compound was active in vivo in HCT116 xenograft model after oral administration and is presently in Phase I clinical trials evaluation. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.03.054
• 作为产物：
  描述：

  5-(1-甲基-1,2,3,6-四氢-吡啶-4-基)-2-三氟甲氧基-苯基胺 在 钯 crude residue 、 silica gel 、 Ammonia methanol dichloromethane 作用下， 以 乙醇 为溶剂， 反应 6.0h， 以to yield the title compound as a light brown solid (0.17 g, 56% yield)的产率得到5-(1-甲基-哌啶-4-基)-2-三氟甲氧基-苯基胺
  参考文献：
  名称：

  SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS

  摘要：

  本发明揭示了式（I）中所定义的吡唑并喹唑啉衍生物及其药学上可接受的盐，以及它们的制备方法和包含它们的制药组合物；本发明中的化合物在治疗与蛋白激酶活性失调相关的疾病，如癌症中可能有用。

  公开号：

  US20100216808A1

文献信息

• SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS
  申请人：Caruso Michele

  公开号：US20100216808A1

  公开（公告）日：2010-08-26

  Pyrazolo-quinazoline derivatives of formula (I) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.

  本发明揭示了式（I）中所定义的吡唑并喹唑啉衍生物及其药学上可接受的盐，以及它们的制备方法和包含它们的制药组合物；本发明中的化合物在治疗与蛋白激酶活性失调相关的疾病，如癌症中可能有用。
• WO2008/74788
  申请人：——

  公开号：——

  公开（公告）日：——
• US8614220B2
  申请人：——

  公开号：US8614220B2

  公开（公告）日：2013-12-24
• [EN] SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE PYRAZOLO-QUINAZOLINE SUBSTITUÉS, LEUR PROCÉDÉ DE PRÉPARATION ET LEUR UTILISATION EN TANT QU'INHIBITEURS DES KINASES
  申请人：NERVIANO MEDICAL SCIENCES SRL

  公开号：WO2008074788A1

  公开（公告）日：2008-06-26

  [EN] Pyrazolo-quinazoline derivatives of formula (I) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.
  [FR] La présente invention concerne des dérivés de pyrazolo-quinazoline de formule (I) tels que définis dans le mémoire descriptif et leurs sels pharmaceutiquement acceptables, leur procédé de préparation et des compositions pharmaceutiques qui les comprennent. Les composés selon l'invention ont une utilisation thérapeutique pour le traitement de maladies associée à une activité protéine-kinase déréglée telles que le cancer.
• NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor
  作者：Italo Beria、Roberto T. Bossi、Maria Gabriella Brasca、Michele Caruso、Walter Ceccarelli、Gabriele Fachin、Marina Fasolini、Barbara Forte、Francesco Fiorentini、Enrico Pesenti、Daniele Pezzetta、Helena Posteri、Alessandra Scolaro、Stefania Re Depaolini、Barbara Valsasina

  DOI：10.1016/j.bmcl.2011.03.054

  日期：2011.5

  As part of our drug discovery effort, we identified and developed 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as PLK1 inhibitors. We now report the optimization of this class that led to the identification of NMS-P937, a potent, selective and orally available PLK1 inhibitor. Also, in order to understand the source of PLK1 selectivity, we determined the crystal structure of PLK1 with NMS-P937. The compound was active in vivo in HCT116 xenograft model after oral administration and is presently in Phase I clinical trials evaluation. (C) 2011 Elsevier Ltd. All rights reserved.